pero inzulínové opticlik
sanofi aventis deutschland gmbh. industriepark hochst 65926 frankfurt am main nemecko -
systém transportný niclas
human care hc lifts ab lund Švédsko -
knižnica príkazov nástroja icl, dcl
medtronic inc. 710 medtronic parkway 554 32 minneapolis, mn (minnesota) spojené štáty americké -
diklofenak-dietylamín teva 23,2 mg/g gél
teva b.v., holandsko - diklofenak - 29 - antirheumatica, antiphlogistica, antiuratica
diklofenak-dietylamín teva 11,6 mg/g gél
teva b.v., holandsko - diklofenak - 29 - antirheumatica, antiphlogistica, antiuratica
diklofenak/mizoprostol cipla 50 mg/0,2 mg
cipla europe nv - diklofenak, kombinácie - 29 - antirheumatica, antiphlogistica, antiuratica
diklofenak/mizoprostol cipla 75 mg/0,2 mg
cipla europe nv - diklofenak, kombinácie - 29 - antirheumatica, antiphlogistica, antiuratica
itami 140 mg liečivá náplasť
fidia farmaceutici s.p.a., taliansko - diklofenak - 29 - antirheumatica, antiphlogistica, antiuratica
dicloepoter
mylan ireland limited, Írsko - diklofenak - 29 - antirheumatica, antiphlogistica, antiuratica
faslodex
astrazeneca ab - fulvestrant - neoplazmy prsníkov - endokrinné terapia, anti-estrogény - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. v pre - alebo perimenopauzálnych žien, kombinácia liečby s palbociclib by mali byť kombinované s luteinizačného hormónu uvoľňujúci hormón (lhrh) agonist.